We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FUJIFILM (FUJIY) & UCDI to Develop Hydrogen-Oxidizing Bacteria
Read MoreHide Full Article
FUJIFILM Holdings Corporation (FUJIY - Free Report) has announced an agreement with the Utilization of Carbon Dioxide Institute or “UCDI” to develop technology for producing organic matter using hydrogen-oxidizing bacteria and carbon dioxide.
The companies are focusing on producing alanine, a type of amino acid, through mass fermentation of UCDI's unique hydrogen-oxidizing bacteria. The collaboration aims to achieve stable mass fermentation of UCDI Hydrogen Bacteria and develop mass production technology for alanine.
Hydrogen-oxidizing bacteria is a type of microorganism that can use carbon dioxide as a source of nutrition and rapidly produce organic matter through a carbon-negative process. This has garnered interest as a potential means of achieving a decarbonized society, which is a pressing issue for the global community.
UCDI Hydrogen Bacteria possess advanced proliferative ability and can produce various organic matter, including amino acids and alcohol, through genetic modification.
Fujifilm has a history of using production technology, including microbial fermentation and cell culture, to manufacture biopharmaceuticals, and has also developed a next-generation continuous production system for integrated biopharmaceutical production.
In November, FUJIFILM announced an investment of $188 million to build a cell culture media manufacturing facility in North Carolina. The facility will help the company to tap into the growing demand for high-quality cell culture media solutions.
Prior to that, the company announced that it will establish a Japanese Bio-CDMO site in Toyama City to develop vaccines against future pandemics. It is expected to become operational by fiscal 2026. The company is investing ¥90 billion (roughly $850 Million) investment package to accelerate growth of its core Bio CDMO subsidiary.
FUJIFILM expects revenues of ¥2,800 billion for the current year, up from the earlier guidance of ¥2,700 billion, indicating growth of 10.9% year over year. The net income is expected to decline 5.3% year over year to ¥200 billion.
At present, FUJIY carries a Zacks Rank #3 (Hold). The stock has lost 14.2% in the past year compared with the sub-industry’s decline of 32.1%.
The Zacks Consensus Estimate for Arista Networks 2022 earnings is pegged at $4.37 per share, up 8.2% in the past 60 days. The long-term earnings growth rate is anticipated to be 17.5%.
Arista Networks’ earnings beat the Zacks Consensus Estimate in the last four quarters, the average being 12.7%. Shares of ANET have declined 18.4% in the past year.
The Zacks Consensus Estimate for Jabil’s 2023 earnings is pegged at $8.31 per share, rising 1.6% in the past 60 days. The long-term earnings growth rate is anticipated to be 12%.
Jabil’s earnings beat the Zacks Consensus Estimate in all the last four quarters, the average being 8.9%. Shares of JBL have declined 3.6% in the past year.
The Zacks Consensus Estimate for Super Micro Computer’s fiscal 2023 earnings is pegged at $9.58 per share, rising 19.8% in the past 60 days.
Super Micro Computer’s earnings beat the Zacks Consensus Estimate in all the last four quarters, the average being 9.4%. Shares of SMCI have soared 83.6% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FUJIFILM (FUJIY) & UCDI to Develop Hydrogen-Oxidizing Bacteria
FUJIFILM Holdings Corporation (FUJIY - Free Report) has announced an agreement with the Utilization of Carbon Dioxide Institute or “UCDI” to develop technology for producing organic matter using hydrogen-oxidizing bacteria and carbon dioxide.
The companies are focusing on producing alanine, a type of amino acid, through mass fermentation of UCDI's unique hydrogen-oxidizing bacteria. The collaboration aims to achieve stable mass fermentation of UCDI Hydrogen Bacteria and develop mass production technology for alanine.
Hydrogen-oxidizing bacteria is a type of microorganism that can use carbon dioxide as a source of nutrition and rapidly produce organic matter through a carbon-negative process. This has garnered interest as a potential means of achieving a decarbonized society, which is a pressing issue for the global community.
Fujifilm Holdings Corp. Price and Consensus
Fujifilm Holdings Corp. price-consensus-chart | Fujifilm Holdings Corp. Quote
UCDI Hydrogen Bacteria possess advanced proliferative ability and can produce various organic matter, including amino acids and alcohol, through genetic modification.
Fujifilm has a history of using production technology, including microbial fermentation and cell culture, to manufacture biopharmaceuticals, and has also developed a next-generation continuous production system for integrated biopharmaceutical production.
In November, FUJIFILM announced an investment of $188 million to build a cell culture media manufacturing facility in North Carolina. The facility will help the company to tap into the growing demand for high-quality cell culture media solutions.
Prior to that, the company announced that it will establish a Japanese Bio-CDMO site in Toyama City to develop vaccines against future pandemics. It is expected to become operational by fiscal 2026. The company is investing ¥90 billion (roughly $850 Million) investment package to accelerate growth of its core Bio CDMO subsidiary.
FUJIFILM expects revenues of ¥2,800 billion for the current year, up from the earlier guidance of ¥2,700 billion, indicating growth of 10.9% year over year. The net income is expected to decline 5.3% year over year to ¥200 billion.
At present, FUJIY carries a Zacks Rank #3 (Hold). The stock has lost 14.2% in the past year compared with the sub-industry’s decline of 32.1%.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks from the broader technology space are Arista Networks (ANET - Free Report) , Jabil (JBL - Free Report) and Super Micro Computer (SMCI - Free Report) , each presently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Arista Networks 2022 earnings is pegged at $4.37 per share, up 8.2% in the past 60 days. The long-term earnings growth rate is anticipated to be 17.5%.
Arista Networks’ earnings beat the Zacks Consensus Estimate in the last four quarters, the average being 12.7%. Shares of ANET have declined 18.4% in the past year.
The Zacks Consensus Estimate for Jabil’s 2023 earnings is pegged at $8.31 per share, rising 1.6% in the past 60 days. The long-term earnings growth rate is anticipated to be 12%.
Jabil’s earnings beat the Zacks Consensus Estimate in all the last four quarters, the average being 8.9%. Shares of JBL have declined 3.6% in the past year.
The Zacks Consensus Estimate for Super Micro Computer’s fiscal 2023 earnings is pegged at $9.58 per share, rising 19.8% in the past 60 days.
Super Micro Computer’s earnings beat the Zacks Consensus Estimate in all the last four quarters, the average being 9.4%. Shares of SMCI have soared 83.6% in the past year.